APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin

Sophie Uzureau, Laurence Lecordier, Pierrick Uzureau, Dorle Hennig, Jonas H Graversen, Fabrice Homblé, Pepe Ekulu Mfutu, Fanny Oliveira Arcolino, Ana Raquel Ramos, Rita M La Rovere, Tomas Luyten, Marjorie Vermeersch, Patricia Tebabi, Marc Dieu, Bart Cuypers, Stijn Deborggraeve, Marion Rabant, Christophe Legendre, Søren K Moestrup, Elena LevtchenkoGeert Bultynck, Christophe Erneux, David Pérez-Morga, Etienne Pays

Research output: Contribution to journalArticlepeer-review

179 Downloads (Pure)

Abstract

The C-terminal variants G1 and G2 of apolipoprotein L1 (APOL1) confer human resistance to the sleeping sickness parasite Trypanosoma rhodesiense, but they also increase the risk of kidney disease. APOL1 and APOL3 are death-promoting proteins that are partially associated with the endoplasmic reticulum and Golgi membranes. We report that in podocytes, either APOL1 C-terminal helix truncation (APOL1Δ) or APOL3 deletion (APOL3KO) induces similar actomyosin reorganization linked to the inhibition of phosphatidylinositol-4-phosphate [PI(4)P] synthesis by the Golgi PI(4)-kinase IIIB (PI4KB). Both APOL1 and APOL3 can form K+ channels, but only APOL3 exhibits Ca2+-dependent binding of high affinity to neuronal calcium sensor-1 (NCS-1), promoting NCS-1-PI4KB interaction and stimulating PI4KB activity. Alteration of the APOL1 C-terminal helix triggers APOL1 unfolding and increased binding to APOL3, affecting APOL3-NCS-1 interaction. Since the podocytes of G1 and G2 patients exhibit an APOL1Δ or APOL3KO-like phenotype, APOL1 C-terminal variants may induce kidney disease by preventing APOL3 from activating PI4KB, with consecutive actomyosin reorganization of podocytes.

Original languageEnglish
Pages (from-to)3821-3836.e13
JournalCell Reports
Volume30
Issue number11
DOIs
Publication statusPublished - 17 Mar 2020

Funding

We acknowledge M.A. Saleem (University of Bristol, UK), J.B. Kopp (NIH, USA), M. Deleu (University of Gembloux, Belgium), L. van den Heuvel (University of Leuven, Belgium), M.A. Elmonem (University of Leuven, Belgium and University of Cairo, Egypt), and V. Martens (University of Brussels, Belgium) for providing the original podocyte cell line, G0/G0 and G1/G2 urinary podocytes, PI(4)P-containing liposomes, and help in generating and cultivating podocyte lines. This work was supported by the European Research Council (ERC) grant 669007-APOLs (to E.P.), grant 11O1614N from the Research Foundation Flanders (to B.C.), and grants J.0078.18 and J.0091.17 from the Belgian Fonds de la Recherche Scientifique (FRS) (to C.E. and D.P.-M. respectively). S.U. is Charg\u00E9 de Recherche FRS, and F.H. is Directeur de Recherche FRS. A.R.R. is supported by a T\u00E9l\u00E9vie fellowship. The CMMI is supported by the European Regional Development Fund and the Walloon Region. Computational resources were provided by the Flemish Supercomputer Center at the University of Antwerp (CalcUA). E.P. and S.U. conceived the work; S.U. L.L. P.U. D.H. J.H.G. F.H. P.E.M. F.O.A. A.R.R. R.M.L.R. T.L. M.V. P.T. M.D. and M.R. performed the experiments and/or the generation of cell lines or tissue samples; B.C. and S.D. analyzed the DNA of the different cell lines; S.U. C.L. S.K.M. E.L. G.B. C.E. D.P.-M. and E.P. supervised different aspects of the experimental plan; E.P. and S.U. wrote the paper. The authors declare no competing interests. We acknowledge M.A. Saleem (University of Bristol, UK), J.B. Kopp (NIH, USA), M. Deleu (University of Gembloux, Belgium), L. van den Heuvel (University of Leuven, Belgium), M.A. Elmonem (University of Leuven, Belgium and University of Cairo, Egypt), and V. Martens (University of Brussels, Belgium) for providing the original podocyte cell line, G0/G0 and G1/G2 urinary podocytes, PI(4)P-containing liposomes, and help in generating and cultivating podocyte lines. This work was supported by the European Research Council (ERC) grant 669007-APOLs (to E.P.), grant 11O1614N from the Research Foundation Flanders (to B.C.), and grants J.0078.18 and J.0091.17 from the Belgian Fonds de la Recherche Scientifique (FRS) (to C.E. and D.P.-M., respectively). S.U. is Charg\u00E9 de Recherche FRS, and F.H. is Directeur de Recherche FRS. A.R.R. is supported by a T\u00E9l\u00E9vie fellowship . The CMMI is supported by the European Regional Development Fund and the Walloon Region . Computational resources were provided by the Flemish Supercomputer Center at the University of Antwerp (CalcUA).

FundersFunder number
Waalse Gewest
KULeuven
CalcUA
University of Bristol, UK)
University of Leuven, Belgium and University of Cairo
Universiteit Antwerpen
European Regional Development Fund
University of BrusselsG0/G0
Horizon 2020 Framework Programme669007
European Research Council11O1614N
Fonds Wetenschappelijk OnderzoekJ.0078.18

    Keywords

    • actomyosin cytoskeleton
    • APOL1
    • APOL3
    • kidney disease
    • MYH9
    • NCS-1
    • phosphoinositide control
    • PI4KB
    • sleeping sickness

    Fingerprint

    Dive into the research topics of 'APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin'. Together they form a unique fingerprint.

    Cite this